.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Deloitte
Daiichi Sankyo
Federal Trade Commission
Farmers Insurance
Harvard Business School
Cantor Fitzgerald
US Department of Justice
Queensland Health
Citi

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,586,551

« Back to Dashboard

Which drugs does patent 8,586,551 protect, and when does it expire?


Patent 8,586,551 protects DIFICID and is included in one NDA. There has been one Paragraph IV challenge on Dificid.

This patent has ninety-three patent family members in twenty-five countries.

Summary for Patent: 8,586,551

Title:18-membered macrocycles and analogs thereof
Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.
Inventor(s): Shue; Youe-Kong (Carlsbad, CA), Hwang; Chan-Kou (San Diego, CA), Chiu; Yu-Hung (San Diego, CA), Romero; Alex (San Diego, CA), Babakhani; Farah (San Diego, CA), Sears; Pamela (San Diego, CA), Okumu; Franklin (Oakland, CA)
Assignee: Optimer Pharmaceuticals, Inc. (Jersey City, NJ)
Application Number:12/551,056
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms LlcDIFICIDfidaxomicinTABLET;ORAL201699-001May 27, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,586,551

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,859,510Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof► Subscribe
7,378,508Polymorphic crystalline forms of tiacumicin B► Subscribe
8,883,986Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof► Subscribe
8,728,796Tiacumicin production► Subscribe
7,906,48918-membered macrocycles and analogs thereof► Subscribe
8,518,899Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof► Subscribe
7,863,249Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof► Subscribe
7,507,564Tiacumicin production► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,586,551

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel199984► Subscribe
HungaryE031581► Subscribe
China101663312► Subscribe
China102503994► Subscribe
China102614207► Subscribe
China102746353► Subscribe
Cyprus1115834► Subscribe
Cyprus1117501► Subscribe
Denmark1539977► Subscribe
Denmark2070530► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Citi
Julphar
Medtronic
McKinsey
US Department of Justice
Moodys
AstraZeneca
Healthtrust
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot